We recurrently detected NF1 loss-of-function mutations as well as activating mutations in RAS and its analogues in clinical samples from ALK inhibitor-resistant neuroblastomas and confirmed the causal contribution of these mutations to ALK inhibitor resistance in preclinical models. This evidence concerns the gene NF1 and neuroblastoma.